FREE SHIPPING ON ORDERS OVER $300 – PLUS A FREE GIFT WITH PURCHASE AS THANKS FOR YOUR SUPPORT

Cerebrolysin

SKU CBL60 Categories ,

$145.00

 

Cerebrolysin does not have a single chemical formula.  It is a biological natural mixture of many low-molecular-weight peptides and free amino acids; because it is a natural, complex extract, it cannot be written as one simple chemical equation. The free amino acid profile includes basic human building blocks like Glutamic Acid, Aspartic Acid, Lysine, and Leucine, similar to natural brain proteins.

CAS Registry Number: 

12656-61-0

 

  • Cognitive Decline & Dementia: Studied for potential improvements in memory, executive function, and daily living performance in Alzheimer’s disease and vascular dementia.

  • Traumatic Brain Injury & Stroke Recovery: Evaluated for supporting neuronal repair, reducing secondary injury cascades, and improving functional rehabilitation outcomes.

  • Neurodevelopmental & Cognitive Disorders: Explored in select studies for attention, processing speed, and neurobehavioral modulation.

  • Neuroprotection & Aging: Investigated for its ability to counteract oxidative stress, excitotoxicity, and mitochondrial dysfunction associated with aging and chronic neurodegeneration.

  • Neurotrophic Signaling: Activation of pathways associated with BDNF and NGF, supporting synaptic plasticity, dendritic growth, and neuronal survival.

  • Mitochondrial Optimization: Enhancement of neuronal energy metabolism, improved ATP generation, and stabilization of mitochondrial function.

  • Anti‑Oxidative & Anti‑Excitotoxic Effects: Reduction of ROS, modulation of glutamate‑induced excitotoxicity, and attenuation of inflammatory cascades.

  • Synaptic Repair & Cognitive Support: Promotion of synaptic efficiency and neurogenesis in regions associated with learning and memory.

Cerebrolysin is pharmaceutically registered in several countries across Europe and Asia for neurological indications. In Canada and the United States, it is not an approved therapeutic drug, and its use remains within research, investigational, or off‑label contexts. Clinical studies show promising outcomes in certain populations, though regulatory bodies continue to call for larger, more standardized trials to establish definitive therapeutic efficacy.

  1. Cui S, Chen N, Yang M, Guo J, Zhou M, Zhu C, He L. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2019 Nov 11
  2. Brainin M. Cerebrolysin: a multi-target drug for recovery after stroke. Expert Rev Neurother. 2018 Aug;18(8):681-687. 
  3. Plosker GL, Gauthier S. Cerebrolysin: a review of its use in dementia. Drugs Aging. 2009;26(11):893-915.
  4. Vester JC, Buzoianu AD, Florian SI, Hömberg V, Kim SH, Lee TMC, Matula C, Poon WS, Sandesc D, von Steinbüchel N, Strilciuc S, Vos PE, von Wild K, Muresanu D. Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurol Sci. 2021 Nov;42(11):4531-4541. 
  5. Gavrilova SI, Alvarez A. Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer’s disease: 30 years of clinical use. Med Res Rev. 2021 Sep;41(5):2775-2803.
  6. Allegri RF, Guekht A. Cerebrolysin improves symptoms and delays progression in patients with Alzheimer’s disease and vascular dementia. Drugs Today (Barc). 2012 Apr;48 Suppl A:25-41. 

CURRENT BATCH LOT NUMBER: CBL602026-05-29

CERTIFICATE OF ANALYSIS – TGMPURE CEREBROLYSIN 60 MG (CBL602026-05-29)

full product description

Cerebrolysin is a low‑molecular‑weight neuropeptide formulation derived from purified porcine brain proteins, designed to deliver peptide fragments capable of crossing the blood–brain barrier. These peptides mimic endogenous neurotrophic factors such as BDNF, NGF, GDNF, and CNTF, supporting neuronal growth, repair, and survival.

Across decades of investigation, Cerebrolysin has been studied for its multimodal neuroprotective and neurotrophic effects, influencing key pathways involved in neuroplasticity, mitochondrial function, oxidative stress reduction, and synaptic signaling. Research highlights activation of PI3K/Akt, MAPK, and CREB‑related cascades, contributing to improved neuronal energy metabolism and enhanced synaptic efficiency .

Clinically, Cerebrolysin has been evaluated in cognitive impairment, traumatic brain injury, and various neurodegenerative conditions, with studies reporting improvements in memory, processing speed, and functional recovery in certain populations. Evidence for vascular dementia and Alzheimer’s disease shows possible cognitive benefits, though higher‑quality trials are still needed for definitive conclusions. It is also used as an adjunct therapy in stroke and TBI management in several Eurasian countries, where it holds pharmaceutical registration .

Its safety profile is generally well‑documented, with most reported effects being mild and transient—such as headache or dizziness—when administered according to established protocols. However, research notes variability in outcomes across indications, and regulatory approval differs internationally, with Cerebrolysin not approved as a therapeutic drug in the United States or Canada.

QUANTITY: 60 MG

Join Waitlist We will inform you when the product arrives in stock. Please leave your valid email address below.